Alopecia Areata

185 registered clinical trials studyying Alopecia Areata — 35 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) NCT07533006	Eli Lilly and Company	Phase 2
Not Yet Recruiting	Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata NCT07453238	Hayat Abad Medical Complex, Peshawar	Phase 4
Enrolling By Invitation	Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata NCT07499713	Istanbul Training and Research Hospital	—
Not Yet Recruiting	Topical Methotrexate vs Minoxidil for Localized Alopecia Areata NCT07459933	Jinnah Postgraduate Medical Centre	Phase 4
Not Yet Recruiting	Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US NCT07226531	Pfizer	—
Not Yet Recruiting	Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) NCT07406204	Hayat Abad Medical Complex, Peshawar	Phase 4
Recruiting	Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome NCT07242638	Icahn School of Medicine at Mount Sinai	Phase 2
Not Yet Recruiting	LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in NCT07336641	Fondazione ISIDE	—
Recruiting	A Study of LAD603 in Adults With Alopecia Areata NCT07311564	Almirall, S.A.	Phase 2
Recruiting	PALLAS Laser for Skin Diseases NCT07250997	Szeged University	N/A
Recruiting	A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. NCT07205159	Forte Biosciences, Inc.	Phase 1
Recruiting	A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata NCT07136467	AbbVie	—
Recruiting	Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata NCT06747611	University of Minnesota	Phase 2
Recruiting	Intralesional Cyclosporine for Alopecia Areata NCT07029204	University of California, Davis	EARLY_Phase 1
Recruiting	Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata NCT07133308	Sun Pharmaceutical Industries, Inc.	Phase 3
Recruiting	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants NCT07023302	AbbVie	Phase 3
Recruiting	A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata NCT06873945	Pfizer	Phase 3
Active Not Recruiting	Comparison of Microneedling Along With Topical Vitamin D3 Versus Microneedling in Alopecia Areata NCT07243977	Services Institute of Medical Sciences, Pakistan	N/A
Not Yet Recruiting	Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Activ NCT06797310	National Taiwan University Hospital	Phase 2
Completed	Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs NCT07174011	Cairo University	Phase 4
Recruiting	A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo NCT06602232	Dren Bio	Phase 1
Not Yet Recruiting	Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata NCT06399783	Assiut University	Phase 4
Recruiting	Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata NCT06104839	NEXTGEN Bioscience	Phase 2
Recruiting	Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alop NCT06564805	Universidad Autonoma de Nuevo Leon	N/A
Recruiting	Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib NCT06531109	Pfizer	—
Recruiting	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study NCT06573593	Second Affiliated Hospital, School of Medicine, Zhejiang University	—
Recruiting	Dupilumab in the Treatment of Pediatric Alopecia Areata NCT05866562	Icahn School of Medicine at Mount Sinai	Phase 2
Active Not Recruiting	A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in A NCT06444451	Sanofi	Phase 2
Active Not Recruiting	A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Are NCT06340360	Nektar Therapeutics	Phase 2
Terminated	DPCP for the Treatment of Alopecia Areata NCT03651752	University of Minnesota	Phase 3
Recruiting	CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry NCT06562270	CorEvitas	—
Active Not Recruiting	Litfulo Capsules Special Investigation NCT06279221	Pfizer	—
Completed	Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin NCT06324695	Universitätsklinikum Hamburg-Eppendorf	N/A
Recruiting	Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser NCT06239324	Egymedicalpedia	Phase 1 / Phase 2
Recruiting	Systemic Treatments for Alopecia Areata Registry NCT06283316	Erasmus Medical Center	—
Completed	The Impact of Untreated Depression and Anxiety Among Patients With Skin Diseases in Jeddah, Saudi Arabia. NCT07046039	King Abdulaziz University	—
Unknown	A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermat NCT06319781	Blueskin AS	—
Recruiting	Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Tre NCT06327581	Zagazig University	N/A
Unknown	Excimer Light(308) Therapy for Resistant Alopecia Areata NCT06149936	Assiut University	—
Unknown	Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata NCT06088147	Al-Azhar University	N/A
Unknown	Evaluation of the Efficacy of Systemic Treatments for Alopecia (ESTAA) NCT06471114	University Hospital, Brest	—
Withdrawn	A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subj NCT06045624	Ornovi, Inc.	Phase 1
Recruiting	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants NCT06012240	AbbVie	Phase 3
Completed	Psychosocial Stress on QOL in Saudi Arabian Patients With Alopecia Areata NCT06802705	University of Jeddah	—
Unknown	Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata. NCT06087796	Assiut University	Phase 1
Active Not Recruiting	A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL NCT06018428	Q32 Bio Inc.	Phase 2
Unknown	Topical Cetirizine in Treatment of Localized Alopecia Areata NCT05803070	Assiut University	—
Active Not Recruiting	Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib NCT06545110	South Valley University	Phase 1
Unknown	Evaluation of Serum Levels of Interlukin-15 and Interlukin-21 in Patients With Alopecia Areata NCT05910138	Sohag University	N/A
Completed	Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care H NCT06278402	Jinnah Hospital	Phase 3
Completed	Evaluation of the Effect of Topical Calcipotriol Versus Platelet-Rich Plasma NCT05954104	Egymedicalpedia	N/A
Unknown	A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological NCT05084417	OM1, Inc.	—
Recruiting	Determinants of Chronic Inflammatory Skin Disease Trajectories NCT05928169	University Hospital Schleswig-Holstein	—
Unknown	Polymorphism of Janus Kinase 1 and 2 (JAK 1&2) in Patients With Alopecia Areata NCT05861401	Sohag University	N/A
Unknown	Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Particip NCT05865041	ASLAN Pharmaceuticals	Phase 2
Recruiting	Regeneron AA Multicenter (Dupilumab) NCT05551793	Emma Guttman	Phase 2
Completed	A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia NCT05650333	Pfizer	Phase 1
Completed	To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of NCT06786689	Sheikh Zayed Medical College	Phase 2
Recruiting	Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopath NCT05398809	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Terminated	Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Al NCT06357169	University of Minnesota	N/A
Unknown	Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Di NCT05587257	Assiut University	N/A
Completed	Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata NCT05589610	Equillium	Phase 2
Completed	Association of TLR7 Gene rs3853839 Polymorphism With Disease Severity in Alopecia Areata: A Case-Control Study NCT07454876	Benha University	—
Unknown	1565nm Non-ablative Fractional Laser Treat Alopecia Areata NCT05744505	Second Affiliated Hospital, School of Medicine, Zhejiang University	N/A
Unknown	Quantification of the Socio-economic Multifacet Burden of Alopecia Areata and Identification of the Associated NCT05588310	University Hospital, Toulouse	—
Terminated	A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata NCT05556265	Bristol-Myers Squibb	Phase 2
Completed	Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata NCT05885269	Combined Military Hospital Abbottabad	Phase 1
Unknown	A Study of KL130008 in Adults With Severe Alopecia Areata NCT05496426	Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.	Phase 2
Recruiting	CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry NCT05745389	CorEvitas	—
Completed	Healthcare Disparities in Alopecia Areata NCT05727306	Momentum Data	—
Unknown	Clinical Application of Stem Cell Educator Therapy in Alopecia Areata NCT04011748	Throne Biotechnologies Inc.	Phase 2
Unknown	Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Area NCT05414266	The University of Texas Health Science Center, Houston	EARLY_Phase 1
Completed	Improving Disease Severity NCT05391178	Wake Forest University Health Sciences	N/A
Unknown	Efficacy of Combined Microneedling With Methotrexate in Treatment of Alopecia Areata NCT05485571	Sohag University	N/A
Completed	Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi. NCT05926882	Jinnah Postgraduate Medical Centre	Phase 4
Unknown	Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia NCT05502952	Sohag University	N/A
Completed	Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata NCT05368103	Amgen	Phase 2
Unknown	Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata NCT05470413	Reistone Biopharma Company Limited	Phase 3
Completed	Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata NCT05255237	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 3
Terminated	Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata NCT05278858	University Hospitals Cleveland Medical Center	Phase 4
Completed	A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Charact NCT06402630	Soterios Ltd	Phase 2
Unknown	A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects NCT05196711	Maxinovel Pty., Ltd.	Phase 1
Unknown	A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-S NCT05205070	AnaptysBio, Inc.	Phase 2
Unknown	Intralesional Vitamin D in Alopecia Areata NCT04660786	Alexandria University	Phase 1 / Phase 2
Recruiting	Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266	Sanguine Biosciences	—
Completed	European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata NCT05041803	Sun Pharmaceutical Industries, Inc.	Phase 3
Completed	The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic NCT05098600	Faculty Hospital Kralovske Vinohrady	—
Withdrawn	Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata NCT03532958	Equillium	Phase 2
Completed	Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata NCT05051761	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 3
Completed	A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata NCT06527729	Assiut University	EARLY_Phase 1
Completed	Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE NCT04797650	Concert Pharmaceuticals	Phase 3
Completed	Sodium Valproate-loaded Nanospanlastics in Patchy Alopecia Areata in Comparison to Topical Steroids NCT05017454	Kasr El Aini Hospital	EARLY_Phase 1
Unknown	Fecal Transplant for Alopecia Areata NCT04833179	Tel-Aviv Sourasky Medical Center	N/A
Unknown	Efficacy of Jessener Solution Versus Intralesional Steroid in Treatment of Alopecia Areata NCT04964349	Al-Azhar University	EARLY_Phase 1
Completed	Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling NCT04338295	Yale University	N/A
Unknown	Excimer Light and Topical Steroid in Treatment of Alopecia Areata NCT04793945	Assiut University	Phase 4
Withdrawn	A Study of JNJ-64304500 in Participants With Alopecia Areata NCT04740970	Janssen Research & Development, LLC	Phase 2
Completed	Clinical Trial to Evaluate Effectiveness of a Probiotic Preparation Administered to Patients With Alopecia Are NCT05599607	Bioithas SL	N/A
Completed	A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia A NCT04784533	Concert Pharmaceuticals	Phase 2
Completed	Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE NCT04518995	Concert Pharmaceuticals	Phase 3
Completed	Tofacitinib for Immune Skin Conditions in Down Syndrome NCT04246372	University of Colorado, Denver	Phase 2
Completed	The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata NCT04239521	Momentum Data	—
Terminated	PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA NCT04517864	Pfizer	Phase 2
Completed	Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata NCT04556734	Pfizer	Phase 2
Completed	A Phase II Study in Patients With Alopecia Areata NCT04346316	Reistone Biopharma Company Limited	Phase 2
Withdrawn	Topical Crisaborole in Patients with Alopecia Areata NCT04299503	Tufts Medical Center	Phase 2
Completed	Comparative Study Efficacy and Safety of of Activated Versus Non-Activated PRP NCT05251831	Al-Azhar University	EARLY_Phase 1
Unknown	Modified SALT Score for Alopecia Areata NCT04412148	Kasr El Aini Hospital	Phase 4
Withdrawn	Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata NCT04238091	Lindsey Bordone	Phase 2
Completed	Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata NCT04034134	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 2
Completed	Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Diox NCT04147845	Alexandria University	N/A
Unknown	Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids NCT04228029	Kasr El Aini Hospital	Phase 4
Unknown	Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata NCT04003376	Assiut University	Phase 4
Completed	Long-Term PF-06651600 for the Treatment of Alopecia Areata NCT04006457	Pfizer	Phase 3
Completed	A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata NCT03899259	Eli Lilly and Company	Phase 3
Unknown	Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis an NCT03976622	University Hospital, Bordeaux	—
Completed	Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata NCT03941548	Concert Pharmaceuticals	Phase 2
Completed	New Treatment of Alopecia Areata NCT05594316	Al-Azhar University	N/A
Active Not Recruiting	Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata NCT03898479	Sun Pharmaceutical Industries, Inc.	Phase 2 / Phase 3
Completed	Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata NCT03811912	Concert Pharmaceuticals	Phase 2
Completed	The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living Wi NCT03873155	University of Sheffield	N/A
Terminated	ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Tot NCT03759340	Aclaris Therapeutics, Inc.	Phase 2
Completed	Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata NCT03800979	Institute of Dermatology, Thailand	Phase 4
Completed	Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata NCT05600673	Ahmed Hassan Nouh MD	Phase 1 / Phase 2
Completed	Superficial Cryotherapy Versus Microneedling in Alopecia Areata NCT04680234	Sohag University	N/A
Active Not Recruiting	A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC NCT03661866	Target PharmaSolutions, Inc.	—
Completed	PF-06651600 for the Treatment of Alopecia Areata NCT03732807	Pfizer	Phase 2 / Phase 3
Unknown	Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation NCT03473600	Assiut University	Phase 4
Completed	Pain Outcomes Following Intralesional Corticosteroid Injections NCT03630198	Vanderbilt University Medical Center	Phase 4
Completed	A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata NCT03570749	Eli Lilly and Company	Phase 2 / Phase 3
Completed	Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopeci NCT03551821	Aclaris Therapeutics, Inc.	Phase 2
Completed	Efficacy and Safety of LH-8 in Paediatric Alopecia Areata NCT03240627	Legacy Healthcare SA	Phase 2 / Phase 3
Completed	Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) NCT03359356	Icahn School of Medicine at Mount Sinai	Phase 2
Terminated	A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata NCT03354637	Aclaris Therapeutics, Inc.	Phase 2
Terminated	Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. NCT03325296	LEO Pharma	Phase 2
Completed	Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata NCT03847441	Aswan University Hospital	N/A
Completed	Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata NCT03137381	Concert Pharmaceuticals	Phase 2
Unknown	Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata NCT03078686	Regeneris Medical	N/A
Unknown	Safety and Efficacy Study of SHAPE Gel in Alopecia Areata NCT02636244	TetraLogic Pharmaceuticals	Phase 2
Completed	Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Are NCT02974868	Pfizer	Phase 2
Completed	Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants NCT02812342	Yale University	Phase 2
Completed	Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of NCT03535233	Cairo University	Phase 4
Completed	Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata NCT02684123	Icahn School of Medicine at Mount Sinai	N/A
Terminated	Topical Garlic Concentrate for Alopecia Areata in Children NCT02691117	Elena Pope	Phase 3
Completed	LEO 124249 Ointment in the Treatment of Alopecia Areata NCT02561585	LEO Pharma	Phase 2
Completed	A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata NCT02684097	Emma Guttman	Phase 2
Completed	TREg Activation in the Treatment of the PELADE (Alopecia Areata) NCT02557074	Centre Hospitalier Universitaire de Nice	Phase 3
Terminated	A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) NCT02553330	Incyte Corporation	Phase 2
Terminated	A Study of Secukinumab for the Treatment of Alopecia Areata NCT02599129	Icahn School of Medicine at Mount Sinai	Phase 2
Unknown	Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females NCT02604888	Mexis George	N/A
Terminated	PAI-1 Expression in Non-scarring Hair Loss NCT02548689	Northwestern University	—
Completed	Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis NCT02299297	Columbia University	Phase 2
Completed	Tofacitinib for the Treatment of Alopecia Areata and Its Variants NCT02312882	Stanford University	N/A
Completed	Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata NCT02350023	Post Graduate Institute of Medical Education and Research, Chandigarh	Phase 4
Completed	The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade NCT02037191	University Hospital, Rouen	Phase 3
Completed	An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type NCT02018042	Columbia University	Phase 2
Completed	Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata NCT01950780	Columbia University	Phase 2
Withdrawn	A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata NCT01917058	Columbia University	Phase 2
Completed	At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644	Sanguine Biosciences	—
Unknown	Excimer Light for Alopecia Areata NCT01802177	University of British Columbia	Phase 2
Terminated	Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia A NCT01840046	Centre Hospitalier Universitaire de Nice	Phase 1 / Phase 2
Unknown	Stem Cell Educator Therapy in Alopecia Areata NCT01673789	Throne Biotechnologies Inc.	Phase 1 / Phase 2
Withdrawn	Childhood Alopecia Areata Study Using the 308-nm Excimer Laser NCT01736007	Phoenix Children's Hospital	N/A
Completed	Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata NCT01559584	Cairo University	N/A
Terminated	Intralesional Steroids in the Treatment of Alopecia Areata NCT01898806	Columbia University	Phase 4
Completed	Vytorin in the Treatment of Alopecia Areata NCT01520077	University of Miami	Phase 1
Completed	The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Al NCT01246284	University of British Columbia	N/A
Completed	Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children NCT01023841	Allergan	Phase 4
Unknown	Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients NCT01017510	Sheba Medical Center	N/A
Unknown	The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata NCT00999869	Siriraj Hospital	N/A
Terminated	Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata NCT01385839	Icahn School of Medicine at Mount Sinai	N/A
Completed	A Study of Vitamin D in Subjects With Alopecia Areata NCT01328678	Avera McKennan Hospital & University Health Center	—
Completed	Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata NCT01797432	University of Minnesota	Phase 2
Completed	Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin NCT00408798	University of British Columbia	N/A
Completed	Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alope NCT00484679	University of Minnesota	Phase 2
Completed	Alefacept in Patients With Severe Scalp Alopecia Areata NCT00167102	University of Minnesota	N/A
Completed	Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia NCT00187577	University of California, San Francisco	N/A
Completed	Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata NCT00063076	M.D. Anderson Cancer Center	Phase 2 / Phase 3
Completed	A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata NCT01453686	The Hospital for Sick Children	Phase 3
Completed	Plaquenil for Alopecia Areata, Alopecia Totalis NCT00176982	Hordinsky, Maria K., MD	Phase 4
Active Not Recruiting	Alopecia Areata Registry NCT00069589	M.D. Anderson Cancer Center	—
Completed	Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% NCT00176943	Hordinsky, Maria K., MD	Phase 4
Completed	Aldara for the Treatment of Extensive Alopecia Areata NCT00177021	Hordinsky, Maria K., MD	Phase 4
Completed	Response of Topical Capsaicin in Alopecia Areata NCT00176969	University of Minnesota	Phase 4
Available	Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600) NCT05522556	Pfizer	—